29岁哈佛学霸，1年开发出“药界ChatGPT”，OpenAI连投三轮，估值92亿

Core Viewpoint - The article discusses the significant advancements in AI-driven drug discovery, particularly highlighting the emergence of Chai Discovery and its innovative AI models, Chai-1 and Chai-2, which are set to revolutionize the pharmaceutical industry by drastically reducing the time and cost associated with drug development [4][19][25]. Financing and Growth - Chai Discovery completed a Series B funding round on December 16, 2025, raising $130 million, bringing its post-money valuation to $1.3 billion (approximately 920 million RMB) [4][5]. - The company has raised a total of $230 million since its inception in 2024, with notable investors including OpenAI, Thrive Capital, and Menlo Ventures [5][6]. Technological Advancements - Chai Discovery aims to transform biology from a descriptive science into an engineering discipline by developing a "molecular computer-aided design suite" [4]. - The company has developed two AI models: Chai-1, which predicts and reprograms biochemical molecules, and Chai-2, which has achieved a success rate of 15%-20% in zero-shot antibody design, compared to a mere 0.1% success rate using traditional methods, marking a hundredfold efficiency improvement [4][19][20]. Market Impact - Chai-2 is referred to as the "ChatGPT of the pharmaceutical industry" because it enables the creation of new proteins directly from target information, significantly shortening the drug discovery timeline from years to weeks [21][24]. - The advancements made by Chai Discovery are expected to address the long-standing challenges of high investment and low output in the pharmaceutical industry, potentially allowing biologists to design life molecules in a programmable manner [25]. Industry Context - The article notes that the AI-driven drug discovery sector is rapidly evolving, with numerous companies globally and in China making strides in this field, indicating a competitive landscape focused on generative AI capabilities [25][26].